Pioglitazone

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

吡格列酮是一种选择性过氧化物酶体增殖物激活受体-γ (PPARγ) 激动剂，用于治疗糖尿病。

Pioglitazone is a selective peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, used to treat diabetes.(In Vitro):Pioglitazone (0.5 or 1 μM, 5 days) can completely prevent AGEs (advanced glycation end-products)-induced β-cell necrosis and the increase of caspase-3 thereby avoiding the impaired viability caused by AGEs in pancreatic beta cell line HIT-T15.Pioglitazone (1 μM, 1 h) can stimulate insulin secretion induced by low glucose concentration and attenuate the GSSG/GSH ratio in cells cultured with AGEs.(In Vivo):Pioglitazone (oral gavage, 10 or 30 mg/kg, once daily, 14 days) can induce improvements in insulin resistance and diabetes that may be lipocalin-dependent in the liver but not in skeletal muscle.Pioglitazone (oral gavage, 10 mg/kg, once daily, 4 weeks) can significantly reduce body weight (BW), cardiac hypertrophy, elevated blood glucose levels and improve the associated dyslipidemia.

——

Animal Model:ob/ob and adipo-/- ob/ob mice with a C57Bl/6 backgroundDosage:10 or 30 mg/kgAdministration:Oral gavage; once daily; 14 daysResult:Showed no changes of serum-free fatty acid and triglyceride levels as well as adipocyte sizes in ob/ob and adipo-/- ob/ob C57BL/6 mice at 10 mg/kg but significantly reduced to a similar degree at 30 mg/kg.Also showed no changes of expressions of TNFα and resistin in adipose tissues of ob/ob and adipo-/- ob/ob mice at 10 mg/kg but decreased at 30 mg/kg.Animal Model:Male Wistar albino rats Dosage:10 mg/kg Administration:Oral gavage; once daily; 4 weeks Result:Decreased the elevated serum levels of both creatinine and creatine kinase-MB (CK-MB), TGF-β1 gene expression and regulated the expression of MMP-2/TIMP-2 system.

U-72107

Metabolic Enzyme/Protease

PPAR

PPAR

Inflammation/Immunology

——

111025-46-8

356.44

C19H20N2O3S

>98% (HPLC)

DMSO: 15 mg/mL (42.08 mM)

O=C(C(S1)CC(C=C2)=CC=C2OCCC3=NC=C(CC)C=C3)[N]C1=O

——

(-20℃)

With Ice Pack

≥ 2 years